dc.contributor.author |
Pargoo, Esmaeel Mohammadi |
|
dc.contributor.author |
Aghasadegh, Mohammad Reza |
|
dc.contributor.author |
Parivar, Kazem |
|
dc.contributor.author |
Bolhassani, Azam |
|
dc.contributor.author |
Nikbin, Mehri |
|
dc.contributor.author |
Rahimi, Pooneh |
|
dc.contributor.author |
Ardestani, Mehdi Shafiee |
|
dc.date.accessioned |
2022-10-28T08:17:07Z |
|
dc.date.available |
2022-10-28T08:17:07Z |
|
dc.date.issued |
2020-03-16 |
|
dc.identifier.issn |
1011-601X |
|
dc.identifier.uri |
http://142.54.178.187:9060/xmlui/handle/123456789/13885 |
|
dc.description.abstract |
Human diseases like viral organisms for example, hepatitis, HIV and etc., attack the health and caused large
mortality in populations by many years. So finding novel delivery vehicles based antiviral drugs employing nanomaterials is of high universal interest. In current approach a very biocompatible biodegradable nano-biopolymer anionic
linear globular dendrimer second generation G2 was elaborately conjugated to a well-known anti-HIV drug Azidovudine
and thereafter was characterized by different analytical techniques like AFM, Zeta sizer, 1HNMR, FTIR and LC-Mass
spectroscopy. Then, Anionic Linear Globular DendrimerG2-Zidovudine Nano-Conjugate was assessed on human normal
cells (toxicity assay by XTT test) and also HIV cell model and the results showed that Anionic Linear Globular
DendrimerG2-Zidovudine Nano-Conjugate Significantly Decreased Retroviral Activity without any human cell toxicity
respectively. Based on current experimental data such nano-compositions is proposed for further in vivo anti-HIV assays
as well. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Karachi: Faculty of Pharmacy & Pharmaceutical Sciecnes, University of Karachi |
en_US |
dc.subject |
Viral organisms |
en_US |
dc.subject |
HIV |
en_US |
dc.subject |
nano-biopolymer anionic linear globular dendrimer second |
en_US |
dc.subject |
Generation G2 |
en_US |
dc.title |
Novel delivery based anionic linear globular dendrimerg2-zidovudine nano-conjugate significantly decreased retroviral activity |
en_US |
dc.type |
Article |
en_US |